Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636519 · ClinicalTrials.gov registry record · Phase 1
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
A Phase 1 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00636519 is a Phase 1 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 36 participants.
The verdict
NCT00636519, a Phase 1 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary purpose of this study is: 1. To evaluate the model determined by the ability of botulism antitoxin (bivalent, Aventis) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage A. 2. To assess the ability of botulism antitoxin (heptavalent, Cangene) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage B.
Interventions
- BIOLOGICAL Botulism Antitoxin Bivalent (Equine) Types A and B
- BIOLOGICAL Botulism Antitoxin Heptavalent (Equine) Types A-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636519
The ClinicalTrials.gov registry entry for NCT00636519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botulism Antitoxin Bivalent (Equine) Types A and B is the first listed.
NCT00636519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00636519 about?
NCT00636519 is a clinical study titled "Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle". The primary purpose of this study is: 1. To evaluate the model determined by the ability of botulism antitoxin (bivalent, Aventis) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage A. 2. To assess the ability of botulism antitoxin (heptavalent, Cangen...
What is the current status of trial NCT00636519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00636519?
The interventions under investigation include: Botulism Antitoxin Bivalent (Equine) Types A and B (BIOLOGICAL), Botulism Antitoxin Heptavalent (Equine) Types A-G (BIOLOGICAL).
Who is sponsoring clinical trial NCT00636519?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.